An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

Tubulin dynamics is a promising target for new chemotherapeutic agents. The colchicine binding site is one of the most important pockets for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. A large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. CBSIs have been modified as to chemical structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers. CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin. The present review is a synopsis of compounds that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.

[1]  David M. Shackleford,et al.  CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo , 2009, Molecular Cancer Therapeutics.

[2]  Chi-Hung Lin,et al.  BPR0C261 is a novel orally active antitumor agent with antimitotic and anti‐angiogenic activities , 2011, Cancer science.

[3]  M. Cushman,et al.  Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate. , 2007, Journal of medicinal chemistry.

[4]  M. Schabel,et al.  Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer , 2010, Molecular Cancer Therapeutics.

[5]  B. Potter,et al.  Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents , 2004, British Journal of Cancer.

[6]  Patrick A. Curmi,et al.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.

[7]  Hai‐Liang Zhu,et al.  Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents. , 2011, Bioorganic & medicinal chemistry.

[8]  A. Brancale,et al.  Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents. , 2011, Journal of medicinal chemistry.

[9]  Yan-Bin Zhang,et al.  Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents. , 2011, Bioorganic & medicinal chemistry.

[10]  J. Brenton,et al.  A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles. , 2012, ACS medicinal chemistry letters.

[11]  Hualiang Jiang,et al.  S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton , 2009, PloS one.

[12]  Yi Chen,et al.  MT119, a new planar‐structured compound, targets the colchicine site of tubulin arresting mitosis and inhibiting tumor cell proliferation , 2011, International journal of cancer.

[13]  S. Ng,et al.  Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent. , 2002, Bioorganic & medicinal chemistry letters.

[14]  G. Giannini,et al.  Novel combretastatin analogues endowed with antitumor activity. , 2006, Journal of medicinal chemistry.

[15]  A. Brossi,et al.  Identification of Cysteine 354 of β-Tubulin as Part of the Binding Site for the A Ring of Colchicine (*) , 1996, The Journal of Biological Chemistry.

[16]  A. Treston,et al.  Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. , 2007, Bioorganic & medicinal chemistry.

[17]  D. Zaharevitz,et al.  A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. , 2005, Journal of medicinal chemistry.

[18]  S. Dutcher.  The tubulin fraternity: alpha to eta. , 2001, Current opinion in cell biology.

[19]  S. Dakshanamurthy,et al.  Polygamain, a New Microtubule Depolymerizing Agent That Occupies a Unique Pharmacophore in the Colchicine Site , 2012, Molecular Pharmacology.

[20]  M. Ubukata,et al.  Tryprostatins A and B, novel mammalian cell cycle inhibitors produced by Aspergillus fumigatus. , 1995, The Journal of antibiotics.

[21]  J. Lippert.  Vascular disrupting agents. , 2007, Bioorganic & medicinal chemistry.

[22]  Lei Wu,et al.  The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. , 2006, Cancer research.

[23]  Concepción Pérez-Melero,et al.  Stilbenophane analogues of deoxycombretastatin A-4. , 2005, The Journal of organic chemistry.

[24]  Mark B. Anderson,et al.  Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity. , 2008, Journal of medicinal chemistry.

[25]  Meredith C Henderson,et al.  UA62784, a novel inhibitor of centromere protein E kinesin-like protein , 2009, Molecular Cancer Therapeutics.

[26]  M. Boyd,et al.  Antineoplastic agents. 379. Synthesis of phenstatin phosphate. , 1998, Journal of medicinal chemistry.

[27]  Raimond B G Ravelli,et al.  Variations in the colchicine-binding domain provide insight into the structural switch of tubulin , 2009, Proceedings of the National Academy of Sciences.

[28]  C. Kanthou,et al.  Vascular Disrupting Agents in Cancer Therapy , 2008 .

[29]  Carlos Alfonso,et al.  Stathmin and Interfacial Microtubule Inhibitors Recognize a Naturally Curved Conformation of Tubulin Dimers* , 2010, The Journal of Biological Chemistry.

[30]  T. Mueller,et al.  4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. , 2010, Journal of medicinal chemistry.

[31]  Arun K. Ghosh,et al.  The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. , 2002, Biochemistry.

[32]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[33]  Chi-Hung Lin,et al.  Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. , 2003, Journal of medicinal chemistry.

[34]  F. Tripodi,et al.  Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis. , 2012, Journal of medicinal chemistry.

[35]  H. Hsieh,et al.  7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. , 2006, Journal of medicinal chemistry.

[36]  Rigid Analogues of Antimitotic Indolobenzazepinones: New Insights into Tubulin Binding via Molecular Modeling. , 2011, ACS medicinal chemistry letters.

[37]  E. Hamel.  Antimitotic natural products and their interactions with tubulin , 1996, Medicinal research reviews.

[38]  W. Hennink,et al.  Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  N. Lawrence,et al.  Synthesis and evaluation of double bond substituted combretastatins. , 2005, European journal of medicinal chemistry.

[40]  S. Baasner,et al.  Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization. , 2011, Bioorganic & medicinal chemistry.

[41]  S. Newman,et al.  IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents , 2008, Molecular Cancer Therapeutics.

[42]  Duane D. Miller,et al.  Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. , 2009, Journal of medicinal chemistry.

[43]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Matei,et al.  Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. , 2009, Gynecologic oncology.

[45]  S. Kuo,et al.  Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents. , 1994, Journal of medicinal chemistry.

[46]  S. Rosenberg,et al.  New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. , 2001, Journal of medicinal chemistry.

[47]  Jan Balzarini,et al.  Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization. , 2007, Journal of medicinal chemistry.

[48]  Qiang Zhang,et al.  Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. , 2009, Cancer research.

[49]  R. Shoemaker,et al.  Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action. , 2012, Journal of medicinal chemistry.

[50]  Xiao-Ping Shi,et al.  Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors. , 2011, Journal of medicinal chemistry.

[51]  H. Hsieh,et al.  Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. , 2011, European journal of medicinal chemistry.

[52]  R. Tjian,et al.  Transcription factor MIZ-1 is regulated via microtubule association. , 2001, Molecular cell.

[53]  J. Liou,et al.  5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. , 2011, Journal of medicinal chemistry.

[54]  C. Bailly,et al.  Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. , 2003, Journal of medicinal chemistry.

[55]  Marlie A. Johnson,et al.  Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. , 2007, Bioorganic & medicinal chemistry letters.

[56]  W. Hennink,et al.  A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy , 2011, International journal of nanomedicine.

[57]  G. Giannini,et al.  Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. , 2008, Journal of medicinal chemistry.

[58]  Regan M. LeBlanc,et al.  SYNTHESIS AND BIOLOGICAL EVALUATION OF CIS-COMBRETASTATIN ANALOGS AND THEIR NOVEL 1,2,3-TRIAZOLE DERIVATIVES , 2005 .

[59]  F. Souard,et al.  A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models , 2009, BMC Cancer.

[60]  P. Wipf,et al.  Synthesis and Biological Evaluation of a Focused Mixture Library of Analogues of the Antimitotic Marine Natural Product Curacin A , 2000 .

[61]  Jonathan E. Hempel,et al.  Identification and Characterization of a New Tubulin-Binding Tetrasubstituted Brominated Pyrrole , 2007, Molecular Pharmacology.

[62]  M. Boyd,et al.  Centaureidin, a cytotoxic flavone from Polymnia fruticosa, inhibits tubulin polymerization , 1993 .

[63]  L. Kotra,et al.  Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships. , 2011, European journal of medicinal chemistry.

[64]  V. Baichwal,et al.  Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. , 2001, Journal of medicinal chemistry.

[65]  F. Giles,et al.  ELR510444, A Novel Microtubule Disruptor with Multiple Mechanisms of Action , 2011, Journal of Pharmacology and Experimental Therapeutics.

[66]  G. Giannini,et al.  Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. , 2005, Journal of medicinal chemistry.

[67]  H. Hsieh,et al.  Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. , 2008, Journal of medicinal chemistry.

[68]  T. Ganesan,et al.  A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer , 2010, British Journal of Cancer.

[69]  Daniel J. Kerr,et al.  The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4. , 2007, Bioorganic & medicinal chemistry.

[70]  S. Kuo,et al.  Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. , 1994, Journal of medicinal chemistry.

[71]  He-long Zhang,et al.  Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. , 2002, Cancer research.

[72]  A. Caldarelli,et al.  Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. , 2011, Journal of medicinal chemistry.

[73]  J. Hartley,et al.  Acetyl analogs of combretastatin A-4: synthesis and biological studies. , 2011, Bioorganic & medicinal chemistry.

[74]  D. Zisterer,et al.  Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents. , 2010, Journal of medicinal chemistry.

[75]  Duane D. Miller,et al.  Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[76]  E. Pasquier,et al.  ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties , 2010, Molecular Cancer Therapeutics.

[77]  H. Cottam,et al.  Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. , 2000, Journal of the National Cancer Institute.

[78]  A. Herrmann,et al.  Reversal of breast cancer resistance protein–mediated drug resistance by tryprostatin A , 2003, International journal of cancer.

[79]  R. Nakagawa,et al.  Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. , 1998, Bioorganic & medicinal chemistry letters.

[80]  Giovanni Sorba,et al.  Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.

[81]  B. Potter,et al.  In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol , 2007, British Journal of Cancer.

[82]  J. Provost,et al.  RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors. , 2000, Molecular pharmacology.

[83]  D. Covell,et al.  Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. , 2000, The Journal of biological chemistry.

[84]  M. Botta,et al.  Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1. , 2012, Bioorganic & medicinal chemistry.

[85]  L. Bohlin,et al.  Podophyllotoxin derivatives : drug discovery and development , 1996 .

[86]  G. Tron,et al.  Synthesis and cytotoxic evaluation of combretafurazans. , 2005, Journal of medicinal chemistry.

[87]  H. Hsieh,et al.  Synthesis and Structure–Activity Relationships of 1‐Benzyl‐4,5,6‐trimethoxyindoles as a Novel Class of Potent Antimitotic Agents , 2009, ChemMedChem.

[88]  Ramesh Chandra,et al.  Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid , 2011, J. Comput. Aided Mol. Des..

[89]  Iman A Y Ghannam,et al.  Synthesis, molecular docking study and antitumor activity of novel 2-phenylindole derivatives. , 2012, European journal of medicinal chemistry.

[90]  L. Kotra,et al.  Design, Synthesis, Biological Evaluation, and Structure–Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4 , 2011, Journal of medicinal chemistry.

[91]  S. Rosenberg,et al.  Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. , 2002, Journal of medicinal chemistry.

[92]  Sergey O Tcherniuk,et al.  UA62784 Is a cytotoxic inhibitor of microtubules, not CENP-E. , 2011, Chemistry & biology.

[93]  N. Nam,et al.  Combretoxazolones: synthesis, cytotoxicity and antitumor activity. , 2001, Bioorganic & medicinal chemistry letters.

[94]  M. Akamatsu,et al.  Synthesis and Structure−Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure , 2012 .

[95]  R. Shoemaker,et al.  Antitumor activity of new substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: selectivity against colon tumor cells and effect on cell cycle-related events. , 2008, Journal of medicinal chemistry.

[96]  Andrea Brancale,et al.  Arylthioindoles, potent inhibitors of tubulin polymerization. , 2004, Journal of medicinal chemistry.

[97]  Ettore Novellino,et al.  Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. , 2011, Journal of medicinal chemistry.

[98]  E. Kraut,et al.  A Phase II Study of CI-980 in Previously Untreated Extensive Small Cell Lung Cancer: An Ohio State University Phase II Research Consortium Study , 2002, Cancer investigation.

[99]  S. Attia.  Molecular cytogenetic evaluation of the mechanism of genotoxic potential of amsacrine and nocodazole in mouse bone marrow cells , 2013, Journal of Applied Toxicology.

[100]  J. Berlin,et al.  The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study , 2006, Clinical Cancer Research.

[101]  M. Steinmetz,et al.  Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.

[102]  Yeong-Rim Kang,et al.  KRIBB3, a novel microtubule inhibitor, induces mitotic arrest and apoptosis in human cancer cells. , 2008, Biochemical pharmacology.

[103]  B. Potter,et al.  Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. , 2010, Journal of medicinal chemistry.

[104]  Ryan S. Davis,et al.  1,2,3,4-tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4. , 2008, European journal of medicinal chemistry.

[105]  R. C.-Gaudreault,et al.  Characterization of the Covalent Binding of N-Phenyl-N′-(2-chloroethyl)ureas to β-Tubulin: Importance of Glu198 in Microtubule Stability , 2011, Journal of Pharmacology and Experimental Therapeutics.

[106]  J. Papon,et al.  Alkylation of β-Tubulin on Glu 198 by a Microtubule Disrupter , 2005, Molecular Pharmacology.

[107]  T. Beckers,et al.  Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. , 2001, Journal of medicinal chemistry.

[108]  C. Gilmore,et al.  Steganacin and steganangin, novel antileukemic lignan lactones from Steganotaenia araliacea. , 1973, Journal of the American Chemical Society.

[109]  Liying Zhang,et al.  Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents. , 2011, Journal of medicinal chemistry.

[110]  B. Potter,et al.  Class III β-tubulin expression and in vitro resistance to microtubule targeting agents , 2009, British Journal of Cancer.

[111]  E. Hamel,et al.  Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents. , 2011, Journal of medicinal chemistry.

[112]  William E. Kemnitzer,et al.  Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group. , 2004, Journal of medicinal chemistry.

[113]  B. Liu,et al.  Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent. , 2011, Journal of medicinal chemistry.

[114]  I. Barasoain,et al.  Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. , 1994, Cancer research.

[115]  William E. Kemnitzer,et al.  Discovery of 4-aryl-2-oxo-2H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. , 2008, Bioorganic & medicinal chemistry letters.

[116]  Duane D. Miller,et al.  Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. , 2010, Journal of medicinal chemistry.

[117]  Y. P. Sachdeva,et al.  Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. , 1997, Journal of medicinal chemistry.

[118]  M. Cushman,et al.  Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization. , 2004, Journal of medicinal chemistry.

[119]  P. Renard,et al.  Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. , 2004, Journal of medicinal chemistry.

[120]  M. Zeller,et al.  A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing. , 2011, European journal of medicinal chemistry.

[121]  N. Nam,et al.  Synthesis and anti-tumor activity of novel combretastatins: combretocyclopentenones and related analogues. , 2002, Bioorganic & medicinal chemistry letters.

[122]  J. Liou,et al.  A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule , 2007, Journal of Pharmacology and Experimental Therapeutics.

[123]  H. Hsieh,et al.  BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo , 2004, Cancer Research.

[124]  J. Desai,et al.  Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation , 2011, Clinical Cancer Research.

[125]  K. Lee,et al.  Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. , 2008, Journal of medicinal chemistry.

[126]  V. Bourgarel-Rey,et al.  Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2. , 2003, Journal of medicinal chemistry.

[127]  G. Tron,et al.  In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes , 2007, Drug Metabolism and Disposition.

[128]  P. Wipf,et al.  Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. , 2002, Journal of medicinal chemistry.

[129]  William E. Kemnitzer,et al.  Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions. , 2008, Journal of medicinal chemistry.

[130]  H. Gourdeau,et al.  Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. , 2004, Molecular cancer therapeutics.

[131]  Qiaojun He,et al.  4,5‐Diaryl‐3‐aminopyrazole Derivatives as Analogs of Combretastatin A‐4: Synthesis and Biological Evaluation , 2011, Archiv der Pharmazie.

[132]  Chieh-Yu Peng,et al.  Antitumor agents 259. Design, syntheses, and structure-activity relationship study of desmosdumotin C analogs. , 2007, Journal of medicinal chemistry.

[133]  J. Chen,et al.  Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents. , 2008, Bioorganic & medicinal chemistry.

[134]  S Seeber,et al.  D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. , 2001, Cancer research.

[135]  M. Hollingshead,et al.  The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization. , 2002, Journal of medicinal chemistry.

[136]  J. Jaén,et al.  Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[137]  J. Bruce,et al.  CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. , 2002, Molecular cancer therapeutics.

[138]  J. Wdzieczak‐Bakala,et al.  New C5-alkylated indolobenzazepinones acting as inhibitors of tubulin polymerization: cytotoxic and antitumor activities. , 2008, Journal of medicinal chemistry.

[139]  H. Hsieh,et al.  5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. , 2010, Journal of medicinal chemistry.

[140]  G. Ecker,et al.  Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs. , 2009, Bioorganic & medicinal chemistry letters.

[141]  S. Ng,et al.  Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. , 2001, Bioorganic & medicinal chemistry letters.

[142]  K. Kanoh,et al.  (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization. , 1999, The Journal of antibiotics.

[143]  D. Haller,et al.  Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[144]  Duane D. Miller,et al.  Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. , 2011, Cancer research.

[145]  D. Scherman,et al.  Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues. , 2011, European journal of medicinal chemistry.

[146]  Liz Y. Han,et al.  Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. , 2007, Cancer research.

[147]  S. Ng,et al.  A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. , 2001, Cancer research.

[148]  B. Wasylyk,et al.  Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. , 2008, Cancer research.

[149]  S. Ng,et al.  Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. , 2003, Molecular cancer therapeutics.

[150]  E. Hamel,et al.  Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198 , 2008, Molecular Cancer Therapeutics.

[151]  D. Gewirtz,et al.  Interference with endothelial cell function by JG-03-14, an agent that binds to the colchicine site on microtubules. , 2009, Biochemical pharmacology.

[152]  L. Qiu,et al.  Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. , 2004, Molecular cancer therapeutics.

[153]  Andrea Brancale,et al.  New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. , 2006, Journal of medicinal chemistry.

[154]  W. Shi,et al.  Preclinical studies of the novel vascular disrupting agent MN-029. , 2005, Anticancer research.

[155]  A. Tolcher,et al.  A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[156]  E. Novellino,et al.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. , 2009, Journal of medicinal chemistry.

[157]  E. Hamel,et al.  The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. , 2001, Bioorganic & medicinal chemistry letters.